The FDA has granted traditional approval to selpercatinib (Retevmo) to treat patients 2 years of age and older who have RET-mutant, advanced or metastatic medullary thyroid cancer and require systemic ...
Plus, you might experience excessive water loss after treatment due to diarrhea or vomiting. So, replenishing fluids in your body is critical ... you may need someone at home to take care of them ...